A retrospective study of treatment of squamous cell carcinoma in situ

Acta Dermato-Venereologica

Volumn 96, Issue 1, 2016, Pages 64-67

  Övermark, Meri ^a   Koskenmies, Sari ^a   Pitkänen, Sari ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bowen s disease; Cryotherapy; Imiquimod; Photodynamic therapy; Retrospective study; Squamous cell carcinoma in situ

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT;

ACTINIC KERATOSIS; ADULT; AGED; AMYLOIDOSIS; ARTICLE; BOWEN DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CAUSE OF DEATH; CHOLANGITIS; CRYOTHERAPY; DERMATOMYOSITIS; EPIDERMODYSPLASIA VERRUCIFORMIS; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GRAFT RECIPIENT; HEMOLYTIC ANEMIA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; POLYMYOSITIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN DEFECT; SUN EXPOSURE; SURGICAL MARGIN; TEMPORAL ARTERITIS; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; FINLAND; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85018223933     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2175     Document Type: Article

References (12)

1. Morton C, Birnie A, Eedy D. British Association of Dermatologist’s guidelines for the management of squamous cell carcinoma in situ (Bowen’s disease) 2014. Br J Dermatol 2014; 170: 245–260.
2. Shimizu I, Gruz A, Chang K, Dufresne R. Treatment of squamous cell carcinoma in situ: a review. Dermatol Surg 2011; 37: 1394–1411.
3. Westers-Attema A, van den Heijkant F, Lohman B, Nelemans P, Winnepenninckx V, Kelleners-Smeets N, et al. Bowen’s disease: a six-year retrospective study of treatment with emphasis on resection margins. Acta Derm Venereol 2014; 94: 431–453.
4. Pitkänen S, Jeskanen L, Ylitalo L. [Basal cell carcinoma, squamous cell carcinoma and premalignant skin lesionshow to treat?] Duodecim 2014; 130: 643–653. (in Finnish).
5. de Berker D, McGregor J, Hughes B. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222–230.
6. Reizner G, Chuang T, Elpern D, Stone J, Farmer E. Bowen’s disease (squamous cell carcinoma in situ) in Kauai, Hawaii. A population-based incidence report. J Am Acad Dermatol 1994; 31: 596–600.
7. Cox N, Eedy D, Morton C. Guidelines for management of Bowen’s disease: 2006 update. Br J Dermatol 2007; 156: 11–21.
8. Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006; 142: 729–735.
9. Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 2007; 156: 793–801.
10. Salim A, Lehman J, McColl J, Chapman R, Morton C. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br J Dermatol 2003; 148: 539–543.
11. Cavicchini S, Serini SM, Fiorani R, Girgenti V, Ghislanzoni M, Sala F. Long-term follow-up of methyl aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen’s disease. Int J Dermatol 2011; 50: 1002–1005.
12. Bath-Hextall F, Matin R, Wilkinson D, Leonardi-Bee J. Interventions for cutaneous Bowen’s disease. Cochrane Database Syst Rev 2013; 6: CD007281.